| CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients B Savoldo, CA Ramos, E Liu, MP Mims, MJ Keating, G Carrum, ... The Journal of clinical investigation 121 (5), 1822-1826, 2011 | 1287 | 2011 |
| Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15 Y Xu, M Zhang, CA Ramos, A Durett, E Liu, O Dakhova, H Liu, ... Blood, The Journal of the American Society of Hematology 123 (24), 3750-3759, 2014 | 830 | 2014 |
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study CRY Cruz, KP Micklethwaite, B Savoldo, CA Ramos, S Lam, S Ku, ... Blood, The Journal of the American Society of Hematology 122 (17), 2965-2973, 2013 | 621 | 2013 |
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins CM Bollard, S Gottschalk, V Torrano, O Diouf, S Ku, Y Hazrat, G Carrum, ... Journal of Clinical Oncology 32 (8), 798-808, 2014 | 555 | 2014 |
| Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem … I Tzannou, A Papadopoulou, S Naik, K Leung, CA Martinez, CA Ramos, ... Journal of Clinical Oncology 35 (31), 3547-3557, 2017 | 459 | 2017 |
| Molecular signatures of proliferation and quiescence in hematopoietic stem cells TA Venezia, AA Merchant, CA Ramos, NL Whitehouse, AS Young, ... PLoS biology 2 (10), e301, 2004 | 437 | 2004 |
| Side-effect management of chimeric antigen receptor (CAR) T-cell therapy ML Schubert, M Schmitt, L Wang, CA Ramos, K Jordan, C Müller-Tidow, ... Annals of oncology 32 (1), 34-48, 2021 | 413 | 2021 |
| Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes CA Ramos, B Ballard, H Zhang, O Dakhova, AP Gee, Z Mei, M Bilgi, ... The Journal of clinical investigation 127 (9), 3462-3471, 2017 | 403 | 2017 |
| Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma CA Ramos, NS Grover, AW Beaven, PD Lulla, MF Wu, A Ivanova, T Wang, ... Journal of clinical oncology 38 (32), 3794-3804, 2020 | 355 | 2020 |
| Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs S Ninomiya, N Narala, L Huye, S Yagyu, B Savoldo, G Dotti, HE Heslop, ... Blood, The Journal of the American Society of Hematology 125 (25), 3905-3916, 2015 | 334 | 2015 |
| Clinical responses with T lymphocytes targeting malignancy-associated κ light chains CA Ramos, B Savoldo, V Torrano, B Ballard, H Zhang, O Dakhova, E Liu, ... The Journal of clinical investigation 126 (7), 2588-2596, 2016 | 322 | 2016 |
| In Vivo fate and activity of second-versus third-generation CD19-Specific CAR-T Cells in B Cell non-hodgkin’s lymphomas CA Ramos, R Rouce, CS Robertson, A Reyna, N Narala, G Vyas, B Mehta, ... Molecular Therapy 26 (12), 2727-2737, 2018 | 286 | 2018 |
| Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy CA Ramos, G Dotti Expert opinion on biological therapy 11 (7), 855-873, 2011 | 282 | 2011 |
| Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue HG Kopp, CA Ramos, S Rafii Current opinion in hematology 13 (3), 175-181, 2006 | 269 | 2006 |
| Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and … AA Kennedy-Nasser, S Ku, P Castillo-Caro, Y Hazrat, MF Wu, H Liu, ... Clinical Cancer Research 20 (8), 2215-2225, 2014 | 237 | 2014 |
| Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion L Amini, SK Silbert, SL Maude, LJ Nastoupil, CA Ramos, RJ Brentjens, ... Nature Reviews Clinical Oncology 19 (5), 342-355, 2022 | 229 | 2022 |
| CAR-T cell therapy for lymphoma CA Ramos, HE Heslop, MK Brenner Annual review of medicine 67 (1), 165-183, 2016 | 182 | 2016 |
| Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma CM Bollard, T Tripic, CR Cruz, G Dotti, S Gottschalk, V Torrano, ... Journal of clinical oncology 36 (11), 1128-1139, 2018 | 177 | 2018 |
| CD19-CAR trials CA Ramos, B Savoldo, G Dotti The Cancer Journal 20 (2), 112-118, 2014 | 159 | 2014 |
| Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma H Tseng, W Xiong, S Badeti, Y Yang, M Ma, T Liu, CA Ramos, G Dotti, ... Nature communications 11 (1), 4810, 2020 | 149 | 2020 |